Toward DNA Sequencing as a Primary Newborn Screen for Treatable Disorders not Amenable to Current Screening
Toward DNA Sequencing as a Primary Newborn Screen for Treatable Disorders not Amenable to Current Screening
批准号:
10228509
负责人:
Renata Constance Gallagher
金额:
$32.3万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-01 至 2023-06-30
关键词:
AddressAffectAllelesAmino AcidsBenignCaliforniaCarbamoyl-Phosphate Synthase (Ammonia)Centers for Disease Control and Prevention (U.S.)Cessation of lifeCharacteristicsChildChromosomesDNADNA sequencingDataData SetDetectionDiagnosisDiseaseEpilepsyEvolutionFutureGenesGenomeGenomicsGenotypeHomocystinuriaInborn Errors of MetabolismIndividualInheritedInterventionLeadModelingNeonatal ScreeningPathogenicityPatientsPerformancePhenotypePopulationPopulation HeterogeneityPublic HealthRecessive GenesRiskSavingsScreening procedureSensitivity and SpecificitySliceSpecificityStructureTestingTimeTrainingUnited StatesUrea cycle disordersVariantVitamin B6Workbasecausal variantcohortdisabilityearly onsetearly screeningexomeexome sequencinggenetic variantgenome sequencingimprovedmachine learning algorithmnovelpredictive modelingscreeningsuccesstandem mass spectrometrywhole genome
中文摘要
我们建议评估全外显子组测序(WES)和全基因组测序
(WGS)作为早期可治疗隐性遗传人群筛查的方法
条件。我们的分析将基于先前和附加的关于大型祖先的工作
1334例先天性代谢性疾病(IEM)全部由不同的儿童队列组成
在加州进行了8.5年的串联质谱学筛查诊断。
我们先前的分析发现,WES缺乏足够的敏感性和特异性来取代
目前采用串联质谱仪(MS/MS)进行新生儿筛查。一种经过筛选优化的
DNA变异解释流水线在MOST中鉴定出两个已知或可能的致病变异,
但不是所有受影响的病例。管道88%的敏感性和98.4%的特异性,数字太低
取代MS/MS我们发现1/3的已知或可能的致病变异是新的,
这大概有2/3是错误的。因此,足够的灵敏度和特异度需要
对错义变体的准确注释。
DNA变体注释侧重于单个变体,最适用于
由单一变种决定其致病性的显性疾病。对于隐性的
疾病,表达是由不同染色体上的两个变异体决定的。我们提出了一个
隐性条件下疾病预测的新框架,其中双等位变异,或
双倍型,用来评估致病性。我们将改进对常染色体的疾病检测
利用DNA测序筛查隐性疾病:1)提高对
利用变异共进化、保守性、氨基酸近似性实现双等位错义变异
和其他特征来得出风险分数,2)考虑隐性致病性中的两个变体
预测,以及3)使用加州新生儿筛查数据集作为具有小的
每种疾病的阳性人数和大量对照(那些阳性的病例
不同的疾病)开发一种机器学习算法来预测疾病的可能性。至
地址敏感度,对于我们数据集中的103个外部阴性IEM病例,我们将全面询问
外显子组数据,既包括已知的IEM基因,也包括整个外显子组,以识别新基因。
最后,对于那些未解决的问题,我们将执行WGS以确定其他原因
变种。在此过程中,我们还将比较WES和WGS在总体敏感度和
筛查的特异性。
我们预计,拟议的研究将是评估DNA的一个重大进步
测序作为一种新生儿筛查工具,用于早期发病的可治疗疾病,
目前没有筛查测试,导致死亡和残疾减少。
英文摘要
We propose to evaluate whole exome sequencing (WES) and whole genome sequencing
(WGS) as an approach for population screening of early-onset treatable recessively inherited
conditions. Our analysis will be based on prior and additional work on the large, ancestrally
diverse cohort of children constituting all 1,334 cases of inborn errors of metabolism (IEM)
diagnosed by tandem mass spectrometry screening in California over an 8.5 year period.
Our prior analysis found that WES lacked adequate sensitivity and specificity to replace
current newborn screening by tandem mass spectrometry (MS/MS). A screening-optimized
DNA variant interpretation pipeline identified two known or likely pathogenic variants in most,
but not all, affected cases. The pipeline was 88% sensitive and 98.4% specific, numbers too low
to replace MS/MS. We found that 1/3 of known or likely pathogenic variants were novel, of
which roughly 2/3 were missense. Adequate sensitivity and specificity therefore require
accurate annotation of missense variants.
DNA variant annotation has focused on individual variants and is most applicable for
dominant disorders for which pathogenicity is determined by a single variant. For recessive
diseases, expression is determined by two variants on different chromosomes. We propose a
new framework for disease prediction in recessive conditions, in which the bi-allelic variants, or
diplotype, is used to assess pathogenicity. We will improve disease detection for autosomal
recessive diseases through screening utilizing DNA sequencing by 1) improving interpretation of
bi-allelic missense variants by using variant co-evolution, conservation, amino acid proximity
and other features to derive a risk score, 2) considering both variants in recessive pathogenicity
prediction, and 3) using the California newborn screening data set as a training set with a small
number of positives for each disorder and a large number of controls (those cases positive for a
different disease) to develop a machine learning algorithm to predict likelihood of disease. To
address sensitivity, for 103 exome negative IEM cases from our data set we will fully interrogate
the exome data, both for known IEM genes and also the entire exome to identify novel genes.
Finally, for those remaining unsolved, we will perform WGS to identify additional causal
variants. In so doing, we will also compare WES and WGS in terms of overall sensitivity and
specificity for screening.
We anticipate that the proposed study will be a significant advance in assessing DNA
sequencing as a newborn screening tool for those early-onset treatable diseases for which there
is currently no screening test, leading to decreased death and disability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金